MyFinsight
Home
Blog
About
Back
Income Statement
Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. (IKT)
source: myfinsight.com
Net loss
-$19,591,231
(-97.58%↓ Y/Y)
Other income
$1,459,764
(59.23%↑ Y/Y)
Loss from operations
-$21,050,995
(-94.34%↓ Y/Y)
Total costs and
expenses
$21,050,995
(94.34%↑ Y/Y)
Research and development
$13,393,464
(154.10%↑ Y/Y)
Selling, general and
administrative
$7,657,531
(29.36%↑ Y/Y)
Back